Get the Stockscreener App
464.56
1.84%
-8.73
After Hours:
465.34
0.78
+0.17%
Alnylam Pharmaceuticals Inc stock is traded at $464.56, with a volume of 671.99K.
It is down -1.84% in the last 24 hours and up +9.70% over the past month.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
See More
Previous Close:
$473.29
Open:
$472.67
24h Volume:
671.99K
Relative Volume:
0.62
Market Cap:
$61.37B
Revenue:
$3.21B
Net Income/Loss:
$43.57M
P/E Ratio:
1,931.64
EPS:
0.2405
Net Cash Flow:
$221.36M
1W Performance:
+4.37%
1M Performance:
+9.70%
6M Performance:
+52.16%
1Y Performance:
+82.38%
1-Day Range:
$464.56
$477.06
1-Week Range:
$444.43
$479.79
52-Week Range:
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Name
Alnylam Pharmaceuticals Inc
Sector
Industry
Phone
(617) 551-8200
Address
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-04-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-04-25 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-30-25 | Resumed | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Mar-31-25 | Initiated | Redburn Atlantic | Buy |
| Mar-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-12-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-16-24 | Upgrade | Goldman | Neutral → Buy |
| Feb-16-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Oct-11-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| May-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-26-23 | Initiated | SMBC Nikko | Neutral |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Buy |
| Sep-09-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-27-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-07-22 | Initiated | William Blair | Outperform |
| Apr-25-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Feb-03-22 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-22-21 | Upgrade | Goldman | Neutral → Buy |
| Nov-22-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-01-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-04-21 | Upgrade | UBS | Neutral → Buy |
| Aug-04-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-22-21 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Feb-12-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-30-20 | Resumed | Berenberg | Hold |
| Sep-08-20 | Initiated | Citigroup | Buy |
| Aug-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| May-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-24-20 | Resumed | Evercore ISI | Outperform |
| Mar-19-20 | Initiated | Berenberg | Buy |
| Dec-19-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-20-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-06-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-05-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-23-19 | Initiated | UBS | Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-18 | Reiterated | Stifel | Buy |
| Aug-07-18 | Upgrade | Stifel | Hold → Buy |
| May-04-18 | Reiterated | Stifel | Hold |
| Mar-28-18 | Initiated | Evercore ISI | In-line |
View All
Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News
Can Alnylam Pharmaceuticals Inc. (DUL) stock sustain institutional flowsPrice Action & Risk Controlled Daily Trade Plans - Newser
What hedge fund activity signals for Alnylam Pharmaceuticals Inc. stock2025 Market Trends & Weekly Watchlist for Hot Stocks - Newser
What dividend safety rating applies to Alnylam Pharmaceuticals Inc. (DUL) stockJuly 2025 WrapUp & Daily Profit Focused Stock Screening - Newser
Is Alnylam Pharmaceuticals Inc. (DUL) stock trading at attractive multiplesJuly 2025 Price Swings & Weekly Hot Stock Watchlists - Newser
Alnylam Pharmaceuticals (ALNY): Is the Stock’s Recent Surge Justified by Its Valuation? - simplywall.st
Will Alnylam Pharmaceuticals Inc. stock benefit from commodity pricesPortfolio Performance Report & Stock Market Timing Techniques - Newser
Is Alnylam Pharmaceuticals Inc. (DUL) stock a fit for income portfoliosWeekly Profit Summary & Low Risk High Win Rate Picks - Newser
Is Alnylam Pharmaceuticals Inc. (DUL) stock prepared for digital transition2025 Price Targets & Low Risk Entry Point Tips - Newser
How Alnylam Pharmaceuticals Inc. stock benefits from tech adoption2025 Technical Overview & Risk Adjusted Buy/Sell Alerts - Newser
Alnylam Pharmaceuticals Announces Changes to Board of Directors - PharmiWeb.com
Alnylam Pharmaceuticals announces changes to board of directors - marketscreener.com
Alnylam announces board changes, appoints Stuart Arbuckle as director By Investing.com - Investing.com India
Quadrature Capital Ltd Trims Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Will Alnylam Pharmaceuticals Inc. (DUL) stock boost dividends furtherJuly 2025 Macro Moves & Free Expert Verified Stock Movement Alerts - Newser
How Alnylam Pharmaceuticals Inc. (DUL) stock reacts to fiscal policies2025 Bull vs Bear & Smart Allocation Stock Reports - Newser
Will Alnylam Pharmaceuticals Inc. (DUL) stock benefit from mergersTrend Reversal & Risk Adjusted Buy/Sell Alerts - Newser
Alnylam Pharma, Atour Lifestyle, MongoDB Among These 10 Stocks Worth Watching - Investor's Business Daily
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years - Benzinga
Options Movement At Alnylam Pharmaceuticals: Yvonne Greenstreet Exercises Worth $1.72M - Benzinga
Can Alnylam Pharmaceuticals Inc. (DUL) stock sustain revenue momentumMarket Movement Recap & AI Powered Market Entry Strategies - Newser
Is Alnylam Pharmaceuticals Inc. (DUL) stock good for wealth creationJuly 2025 Catalysts & High Accuracy Swing Trade Signals - Newser
CRH, Vertiv, Ares, Alnylam Could Be Added to S&P 500 Friday in Rebalancing - Barron's
Spotlight On Alnylam Pharmaceuticals And 2 Other Stocks Possibly Trading Below Fair Value - Yahoo Finance
Alnylam Pharmaceuticals, Inc. (0HD2.L) Stock Price, News, Quote & History - Yahoo! Finance Canada
The Bull Case For Alnylam Pharmaceuticals (ALNY) Could Change Following Raised Sales Guidance for Vutrisiran - simplywall.st
What's Going On With Alnylam Stock On Friday? - Benzinga
Can Alnylam Pharmaceuticals Inc. stock beat market expectations this quarterWeekly Earnings Recap & Technical Confirmation Trade Alerts - moha.gov.vn
Alnylam Pharmaceuticals Reports Strong TTR Growth Amid Challenges - MSN
IPO Launch: Why Alnylam Pharmaceuticals Inc. stock could be next big winnerMarket Risk Analysis & High Conviction Buy Zone Alerts - moha.gov.vn
ETFs Investing in Alnylam Pharmaceuticals, Inc Stocks - TradingView
Thanksgiving: Top 10 Most Innovative BioPharma Drugs In Phase 3 - Seeking Alpha
A Look at Alnylam Pharmaceuticals's Valuation Following Raised Sales Guidance on Vutrisiran Outperformance - simplywall.st
Here’s What Boosted Alnylam Pharmaceuticals (ALNY) in Q3 - MSN
Backdoor AI Beneficiary Yields 8.8%, Trades at 13% Discount - Investing.com
Alnylam’s TTR Franchise Drives Big Revenue Growth And Raises Guidance - Finimize
MoA Mid Cap Growth Fund's Alnylam Pharmaceuticals Inc(ALNY) Holding History - GuruFocus
Alnylam Pharmaceuticals (ALNY): Assessing Valuation After Recent Share Price Pullback - Yahoo Finance
Is Alnylam Pharmaceuticals Stock Justified After 73.9% Surge and Clinical Trial Milestones? - simplywall.st
Small Interfering RNA (siRNA) Therapeutics Market 2025: - openPR.com
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 15 Years - Benzinga
Alnylam's ATTR cardiomyopathy drug backed for NHS use - pharmaphorum
NICE Final Draft Guidance backs Alnylam’s Amvuttra - The Pharma Letter
Why Alnylam Pharmaceuticals Inc. (DUL) stock attracts wealthy investorsJuly 2025 Institutional & Expert Approved Trade Ideas - newser.com
Alnylam Pharmaceuticals Faces Weak Start with 6.56% Gap Down Amid Market Concerns - Markets Mojo
UK's drug-cost watchdog recommends Alnylam's heart disease drug - Reuters
UK’s drug-cost watchdog recommends Alnylam’s heart disease drug - The Mighty 790 KFGO
Alnylam Pharmaceuticals Inc Stock (ALNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):